MedPath

Effect of the Consumption of Alcohol-free Beers With Different Carbohydrates Composition on Postprandial Metabolic Response

Not Applicable
Completed
Conditions
Healthy Diet
Postprandial Hyperglycemia
Interventions
Other: Sub-study 1
Other: Sub-study 2
Registration Number
NCT04790877
Lead Sponsor
Universidad de Zaragoza
Brief Summary

The overall objective of this study is to explore the glycemic index and glycemic load induced by an alcohol-free beer with modified composition (including almost full fermentation of carbohydrates and the addition of isomaltulose and a resistant maltodextrin), as well as its postprandial metabolic response, compared to the effect induced by: a) an alcohol-free beer with a usual composition; b) an alcohol-free beer with modified composition (including almost full fermentation of carbohydrates and the addition of a resistant maltodextrin). This study includes two cross-over sub-studies recruiting healthy participants. In the first one, 10 healthy volunteers receive 25 g of carbohydrates coming from: regular alcohol-free beer (RB), alcohol-free beer with almost completely eliminated maltose and enriched with isomaltulose (2.5 g/100 mL) and a resistant maltodextrin (0.8 g/100 mL) (IMB), alcohol-free beer with the same maltose removal enriched with resistant maltodextrin (2.0 g/100 mL) (MB) and glucose solution. In the second study, 20 healthy volunteers are provided with 50 g of carbohydrates from white bread and water and the same meal plus 14.3 g of carbohydrates coming from: RB, IMB, MB and extra white bread. Blood is sampled at baseline and for 2 h, every 15 min, after ingestion.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • BMI between 18.5 and 27.5 kg/m2.
Exclusion Criteria
  • Presence of cardiometabolic pathology such as dyslipemia (total cholesterol > 200 mg/dL and/or triglycerides > 150 mg/dL, and/or taking lipid-lowering drugs), prediabetes or type 1 or 2 diabetes mellitus (glucose ≥ 100 mg/dL and/or glycosylated hemoglobin ≥ 5.7% and/or taking hypoglycemic drugs) or high blood pressure without drug treatment.
  • Presence of other chronic pathologies that could interfere with the results of the study such as cardiovascular disease, kidney disease, thyroid disease or liver disease.
  • Presence of intestinal malabsorption syndromes and/or presence of Chron disease or ulcerative colitis.
  • Use of drugs that may interfere with lipid and/or glycidic metabolism.
  • Presence of some analytical alteration that could interfere with the results of the study.
  • Increased or decreased body weight of ≥ 5 kg in the last 6 months.
  • Gluten intolerance.
  • Regular intake of functional foods such as phytosterols or red rice yeast, which have a significant effect on lipid or glycidic metabolism, in the last 6 weeks.
  • Intake of vitamin supplements.
  • Hormone replacement therapy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
First sub-study: Alcohol-free beer with modified composition (isomaltulose + maltodextrin)Sub-study 1This intervention entails the intake of an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with isomaltulose (2.5 g/100 mL) and a resistant maltodextrin (0.8 g/100 mL) (IMB). This beverage included 25 g of carbohydrates.
Second sub-study: White bread + WaterSub-study 2This intervention entails the intake of white bread (providing 50 g of carbohydrates) and water.
First sub-study: Glucose beverageSub-study 1This intervention entails the intake of a beverage including 25 g of glucose.
Second sub-study: White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin)Sub-study 2This intervention entails the intake of white bread (providing 50 g of carbohydrates) and an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with isomaltulose (2.5 g/100 mL) and a resistant maltodextrin (0.8 g/100 mL) (IMB). This beverage included 14.3 g of carbohydrates.
First sub-study: Regular alcohol-free beerSub-study 1This intervention entails the intake of regular alcohol-free beer including 25 of carbohydrates.
First sub-study: Alcohol-free beer with modified composition (++ maltodextrin)Sub-study 1This intervention entails the intake of an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with a resistant maltodextrin (2.0 g/100 mL) (MB). This beverage included 25 g of carbohydrates.
Second sub-study: White bread + Alcohol-free beer enriched with ++ maltodextrinSub-study 2This intervention entails the intake of white bread (providing 50 g of carbohydrates) and an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched a resistant maltodextrin (2.0 g/100 mL) (MB). This beverage included 14.3 g of carbohydrates.
Second sub-study: White bread + Regular alcohol-free beerSub-study 2This intervention entails the intake of white bread (providing 50 g of carbohydrates) and regular alcohol-free beer (providing 14.3 g of carbohydrates).
Second sub-study: Extra-White bread + WaterSub-study 2This intervention entails the intake of white bread which provides 64.3 g (50 g + 14.3 g) of carbohydrates and water. This intervention would be the comparator in carbohydrates-equally conditions.
Primary Outcome Measures
NameTimeMethod
GlucoseChange from Baseline to 120-minutes after consumption of the beverage.
GLP-1Change from Baseline to 120-minutes after consumption of the beverage.
GIPChange from Baseline to 120-minutes after consumption of the beverage.
InsulinChange from Baseline to 120-minutes after consumption of the beverage.
Secondary Outcome Measures
NameTimeMethod
Pancreatic polypeptideChange from Baseline to 120-minutes after consumption of the beverage.
LDL cholesterolChange from Baseline to 120-minutes after consumption of the beverage.
LeptinChange from Baseline to 120-minutes after consumption of the beverage.
Polypeptide YChange from Baseline to 120-minutes after consumption of the beverage.
TriglyceridesChange from Baseline to 120-minutes after consumption of the beverage.
GlucagonChange from Baseline to 120-minutes after consumption of the beverage.
GhrelinChange from Baseline to 120-minutes after consumption of the beverage.
HDL cholesterolChange from Baseline to 120-minutes after consumption of the beverage.

Trial Locations

Locations (1)

Instituto de Investigación Sanitaria Aragón, Hospital Universitario Miguel Servet, Universidad de Zaragoza

🇪🇸

Zaragoza, Spain

© Copyright 2025. All Rights Reserved by MedPath